Compare ONEN & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONEN | TLSA |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.6M | 145.1M |
| IPO Year | 2024 | 2017 |
| Metric | ONEN | TLSA |
|---|---|---|
| Price | $1.47 | $0.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.98 |
| AVG Volume (30 Days) | 58.6K | ★ 509.7K |
| Earning Date | 12-23-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $0.57 |
| 52 Week High | $3.07 | $1.90 |
| Indicator | ONEN | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 33.00 |
| Support Level | N/A | $0.57 |
| Resistance Level | $1.71 | $1.21 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 43.44 | 17.65 |
One Nuclear Energy Inc is a development-stage independent power producer focused on developing reliable, high-density, low-carbon baseload electricity and heat generation projects to support energy supply needs in the digital economy. The company's objective is to serve a range of energy-intensive customers across multiple sectors, including data centers, industrial manufacturing, refineries, desalination facilities, and other critical infrastructure users.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.